Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCash from Financing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

BioXcel Therapeutics (BTAI) Depreciation & Amortization (CF) (2022 - 2025)

BioXcel Therapeutics has reported Depreciation & Amortization (CF) over the past 4 years, most recently at $74000.0 for Q4 2025.

  • Quarterly results put Depreciation & Amortization (CF) at $74000.0 for Q4 2025, down 3.9% from a year ago — trailing twelve months through Dec 2025 was $300000.0 (down 2.91% YoY), and the annual figure for FY2025 was $300000.0, down 2.91%.
  • Depreciation & Amortization (CF) for Q4 2025 was $74000.0 at BioXcel Therapeutics, down from $75000.0 in the prior quarter.
  • Over the last five years, Depreciation & Amortization (CF) for BTAI hit a ceiling of $85000.0 in Q3 2022 and a floor of $74000.0 in Q4 2025.
  • Median Depreciation & Amortization (CF) over the past 4 years was $77500.0 (2022), compared with a mean of $78375.0.
  • Peak annual rise in Depreciation & Amortization (CF) hit 3.9% in 2023, while the deepest fall reached 7.06% in 2023.
  • BioXcel Therapeutics' Depreciation & Amortization (CF) stood at $81000.0 in 2022, then dropped by 3.7% to $78000.0 in 2023, then decreased by 1.28% to $77000.0 in 2024, then dropped by 3.9% to $74000.0 in 2025.
  • The last three reported values for Depreciation & Amortization (CF) were $74000.0 (Q4 2025), $75000.0 (Q3 2025), and $75000.0 (Q2 2025) per Business Quant data.